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A Ab bs st tr ra ac ct t
The criteria for the diagnosis of HNPCC established by the ICG-HNPCC are very restrictive as they do not
allow for the diagnosis of a large number of “suspected HNPCC“ cases – these are families which do no fulfill
the strict diagnostic “Amsterdam criteria“, but do present with several pedigree and clinical features characteristic
for HNPCC. Several series of families suspected of harboring germline mutations in DNA mismatch repair genes
have been studied for germline changes in DNA mismatch repair genes and a mutation rate of somewhere
between 8-60% was found. Therefore a subgroup of members of the ICG-HNPCC has been working on
pedigree/clinical diagnostic criteria for suspected HNPCC. 
M Ma at te er ri ia al l   a an nd d   m me et th ho od ds s. .   
P Pa ar rt t   I I. . The study was based on two series of colorectal cancer (CRC) cases: 1) HNPCC – this group comprised
190 patients affected by CRC from randomly selected families which fulfilled the Amsterdam II criteria registered
in Düsseldorf, Germany (102 cases of CRC), Denmark (18 CRCs), Leiden, Holland (23 CRCs) and Szczecin,
Poland (47 CRCs). 2) Consecutive CRCs – this group comprised 629 (78.0%) of 806 individuals with CRC
diagnosed in 1991-1997 in the city of Szczecin (ca. 400,000 of inhabitants), Poland. Nuclear pedigrees in
both groups were compared for frequency of occurrence of clinical features, that have been shown to be
associated with HNPCC. 
P Pa ar rt t   I II I. . 52 consecutive CRC cases from Szczecin, matching the criteria recognized in part I as appropriate
for diagnosis of cases “suspected of HNPCC“ were studied for the occurrence of germline hMSH2/hMLH1
constitutional mutations using “exon by exon“ sequencing. 
R Re es su ul lt ts s. . The combination of features – i.e. the occurrence of an HNPCC associated cancer (CRC or cancer
of the endometrium, small bowel or urinary tract) in a 1st degree relative of a CRC patient; at least one of the
patients being diagnosed under age of 50 – appeared to be strongly associated to HNPCC with an OR – 161.
Constitutional mutations were identified in 18 (10 MLH1 and 8 MSH2 mutations) of 52 (34%) cases matching
the above features. 
C Co on nc cl lu us si io on ns s. . The results of our studies strongly suggest that it is possible to diagnose HNPCC with a high
degree of accuracy on the basis of nuclear pedigree data and clinical features. 
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Hereditary non-polyposis colorectal cancer (HNPCC
– Lynch syndrome) is an autosomal dominant disorder
characterized by the development of colorectal cancer
at an early age, a preponderance of tumors in the
proximal colon, and an excess of multiple primary
cancers [1]. In families with HNPCC extra-colonic
tumors such as cancers of the endometrium, small
bowel, hepatobiliary tract, urinary tract, ovary, stomach
or brain occur with increased frequency [2-5]. Although
genes related to the predisposition of HNPCC have
already  been  cloned  (hMLH1,  hMSH2,  hPMS2,
hMSH6, and hMLH3), the detailed analysis of pedigree
and clinical data remains crucial for the diagnosis of
this disorder when determining a person’s qualification
for surveillance and gene testing [6-10]. According to
the International Collaborative Group on HNPCC
(ICG-HNPCC) the disease can be diagnosed when the
Amsterdam criteria are matched, these being: 1) three
or more relatives with histologically verified colorectal
cancer (CRC), one of whom is first degree to the other
two;  2)  colorectal  cancer  affecting  at  least  two
generations, and 3) one or more colorectal cancer
cases diagnosed under the age of 50 and 4) familial
adenomatous polyposis is excluded [11].
The ICG-HNPCC criteria were revised in 1999
[12]. The term “colorectal cancer“ was changed to
“HNPCC-associated cancer“. HNPCC-associated
cancers include colorectal cancer and cancers of the
endometrium, small bowel, renal pelvis or ureter.
The ICG-HNPCC criteria for the diagnosis of
HNPCC are very restrictive and they do not allow for
the inclusion of a large number of “suspected HNPCC“
cases – that is families that do not fulfill the Amsterdam
criteria, but present with several pedigree and clinical
features characteristic of HNPCC. In several different
series of families suspected of HNPCC but not fulfilling
the diagnostic criteria, germline mutations were found
in 8-60% of kindreds [13-17]. Therefore a subgroup
of members of the ICG-HNPCC has been working on
a pedigree/clinical diagnostic protocol for suspected
cases of HNPCC. Recently, such criteria (shown in
Table 1) were revised by Park et al. [16].
Park et al. (1999) agree that further refinements of
the criteria are needed to improve the identification of
HNPCC families. In our experience the most important
limitations in the application of pedigree/clinical data
in the diagnosis of HNPCC are problems with the
availability of medical documentation of patients’
relatives and the small size of contemporary families.
Therefore, in the study reported here we aimed to
identify criteria based on nuclear pedigree and clinical
analyses whilst maintaining the diagnosis of HNPCC
with a high degree of sensitivity and specificity.
M Ma at te er ri ia al l   a an nd d   m me et th ho od ds s
P Pa ar rt t  I I
The study was based on two series of CRC cases:
1) HNPCC – this group comprised 190 patients
affected by CRC from randomly selected families,
which fulfilled the Amsterdam II criteria registered in
Düsseldorf, Germany (102 cases of CRC), Denmark
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T Ta ab bl le e   2 2. .   Definition of analysed pedigree/clinical features
F Fe ea at tu ur re e   N No o D De ef fi in ni it ti io on n
F1 at least one first degree relative of the index patient with CRC affected by an HNPCC closely associated cancer*
F2 at least one other malignancy associated with HNPCC (cancers of the stomach, hepatobiliary tract, ovary, pancreas 
or gliomas) in a first degree relative of patient with CRC
F3 CRC diagnosed under the age of 50
F4 CRC diagnosed under the age of 40
F5 HNPCC closely associated cancer* diagnosed under the age of 50 in first degree relatives of an index patient with CRC 
* of the colon, rectum, endometrium, small bowel, urinary tract.
T Ta ab bl le e   1 1. .   Revised criteria for the identification of suspected HNPCC
One colorectal cancer patient with at least one of the following:
Presence of synchronous or metachronous colorectal tumors in the patient, one of which occurred under the age of 40 years.
Endometrial, urinary tract, or small-intestinal cancer in the patient or a first degree relative (one aged <50 years).
At least two first degree relatives (one aged <50 years) with other extra-colonic cancers (stomach, hepatobiliary system, ovary, or brain).H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2003; 1(1) 36
(18 CRCs), Leiden, Holland (23 CRCs) and Szczecin,
Poland  (47  CRCs).  For  43  of  these  patients,
information about the occurrence of constitutional
MSH2 or MLH1 mutations were obtained. Patients for
analysis from a given family were selected only from
the youngest generation of individuals affected by
cancers (Fig. 1). This selection system was chosen in
order  to  avoid  bias  related  to  improvements  in
diagnostic  procedures  (colonoscopies  were  less
frequently performed 10 years earlier) and potential
anticipation of age at diagnosis in recent generations.
2) Consecutive CRCs – this group comprised 629
(78.0%) of 806 individuals with recently diagnosed
CRC  in  1991-1997  in  the  city  of  Szczecin  (ca.
400,000 of inhabitants), Poland.
Nuclear pedigrees in both groups were compared
for the occurrence of clinical features that have been
shown to be associated with HNPCC. The analyzed
features are summarized in Table 2.
Univariate statistical analyses – X
2, odds ratio (OR),
confidence interval (CI) - 95%, sensitivity and specificity
were performed using SAS program and LOGIT method. 
P Pa ar rt t  I II I
52 consecutive CRC cases from HCC in Szczecin,
matching F1, (F3 and/or F5) but not Amsterdam II
criteria were studied for the occurrence of germline
hMSH2/hMLH1 constitutional mutations using “exon
by exon“ sequencing.
T Ta ab bl le e   3 3. .   Statistical analysis of nuclear pedigree clinical features of CRC patients from HNPCC families in total
C Cr ri it te er ri iu um m    N No o. .    N No o. .    O OR R C CI I s se en ns si it ti iv vi it ty y s sp pe ec ci if fi ic ci it ty y p p
o of f   H HN NP PC CC C o of f   c co on ns se ec cu ut ti iv ve e
c ca as se es s c ca as se es s
Total 182 % 629 % from to % %
F1    176 96.70 100 15.90 155.2 66.9 359.9 96.70 84.10 0.0000
F2    7 3.85 55 8.74 0.42 0.19 0.9 3.85 91.26 0.0490
F3     142 78.02 102 16.22 18.3 12.2 27.6 78.02 83.78 0.0000
F4     70 38.46 24 3.82 15.8 9.5 26.1 38.46 96.18 0.0000
F5    134 73.63 43 6.84 38 24.2 59.8 73.63 93.16 0.0000
F1 without  6 3.30 80 12.7 0.23 0.10 0.55 3.30 87.3 0.0003
(F3 or/and F5)*
F1 and  170 93.41 51 8.16 160.6 84.2 305.5 93.41 91.84 0.0000
(F3 or/and F5)**
F4 without F1  2 1.10 38 6.04 0.17 0.04 0.72 1.10 93.96 0.0160
and without F2***
* HNPCC closely associated cancer in first degree relative of CRC patient; none of these cancers were diagnosed under the age of 50. 
** HNPCC closely associated cancer in first degree relative of CRC patient; at least one of cancers was diagnosed under the age of 50.
*** sporadic CRC diagnosed under the age of 40.
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H HN NP PC CC C   F Fa am mi il ly y   ( (M Mu ut ta at ti io on n   h hM ML LH H1 1) )
C Co o5 58 8
d d7 71 1
C Co o4 47 7
d d4 47 7
T Tr r5 55 5
6 65 5
M ML LH H1 1+ +
T Tr r4 42 2
M ML LH H1 1+ +
4 45 5
M ML LH H1 1( (- -) )
C Co o3 33 3
d d3 33 3
O Ov v3 39 9
d d3 39 9
2 20 0 1 18 8 2 21 1 1 17 7 1 10 0
Unaffected male or female Co colon
20 d40 Current age or death age Tr transverse colon
Cancer verified by pathology Ov ovary
Co 58 Ov 39 Cancer localisation and age at diagnosis
Cancer established by family history
proband
L Le eg ge en nd d C Ca an nc ce er r   l lo oc ca al li is sa at ti io on n
F Fi ig g. .   1 1. .   S Se el le ec ct ti io on n   o of f   c ca as se es s   f fo or r   n nu uc cl le ea ar r   p pe ed di ig gr re ee e   a an na al ly ys si is s. .   I In nd di iv vi id du ua al ls s
c ch ho os se en n   a ar re e   e en nc ci ir rc cl le ed dH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2003; 1(1) 37
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R Re es su ul lt ts s
The results of the genomic DNA sequencing analyses
are summarized in Table 3. All of the defined features
(F1-F5) were confirmed to be very strongly associated
to HNPCC with an OR of 15 to 155 depending on
which feature was chosen for the clinical and or pedigree
diagnosis. The only exception was feature F2, where it
was impossible to show that the occurrences of cancers
of the stomach, hepatobiliary tract, ovary, pancreas or
gliomas among first degree relatives of CRC patients
are characteristic for HNPCC (OR - 0.42). The strongest
association to HNPCC was the occurrence of one first
degree  relative  with  one  of  either  colon,  rectum,
endometrium, small bowel or urinary tract cancer OR
155.2. However, aggregation of at least two first degree
relatives affected by an HNPCC associated cancer has
been shown not to be characteristic of HNPCC in
families who do not have disease diagnosed under the
age of 50 years (OR – 0.23).
In contrast, combining features F1 and (F3 and/or
F5) – a situation where an HNPCC closely associated
cancer is found in first degree relatives of CRC patients
and one of these cancers is diagnosed under age of
50, appeared to be strongly associated with HNPCC
(OR – 161). The occurrence of sporadic cancer
diagnosed under the age of 40 years (combinations
F4 without F1 and without F2) has been found not to
be characteristic of HNPCC (OR – 0.17).
Similar features and their combinations have been
recognized as being typical of HNPCC in a subgroup
of 43 cases from families with confirmed MSH2 or
MLH1 constitutional mutations (Table 4). Constitutional
mutations were identified in 18 (10 MLH1 and 8 MSH2
mutations) of 52 (34%) cases matching the combination
of features, F1 and (F3 and/or F5). 
D Di is sc cu us ss si io on n
The results of our studies strongly suggest that it is
possible to diagnose HNPCC with a high degree of
accuracy on the basis of nuclear pedigree data and
clinical features alone. One simple criterion – the
occurrence of two or more HNPCC closely associated
cancers (cancer of the colon, rectum, endometrium,
small bowel and urinary tract) in first degree relatives
of patients with CRC with at least one of the cancers
is diagnosed under the age of 50 – can be used to
identify HNPCC with an OR – 161. Unexpectedly, we
found that the diagnosis of suspected HNPCC is not
possible on the basis of nuclear pedigree analysis
alone if patients with CRC are diagnosed under the
age of 40 and without a first degree relative affected
by an HNPCC associated malignancy. 
The analyses performed in this report are an
alternative approach for the diagnosis of HNPCC on
clinical criteria based on the statistical assessment of
the frequency of specifically analyzed features between
the study population and control groups of patients
T Ta ab bl le e   4 4. .   S St ta at ti is st ti ic ca al l   a an na al ly ys si is s   o of f   n nu uc cl le ea ar r   p pe ed di ig gr re ee e   c cl li in ni ic ca al l   f fe ea at tu ur re es s   o of f   C CR RC C   p pa at ti ie en nt ts s   w wi it th h   i id de en nt ti if fi ie ed d   m mu ut ta at ti io on ns s
C Cr ri it te er ri io on n    N No o. .    N No o. .    O OR R C CI I s se en ns si it ti iv vi it ty y s sp pe ec ci if fi ic ci it ty y p p
o of f   H HN NP PC CC C o of f   c co on ns se ec cu ut ti iv ve e
c ca as se es s c ca as se es s
Total 43 % 629 % from to % %
F1    39 90.70 100 15.90 51.6 18.03 147.5 90.70 84.10 0.0000
F2    5 11.63 54 8.59 1.4 0.53 37.1 11.63 91.41 0.4970
F3     41 95.35 102 16.22 105.9 25.22 444.8 95.35 83.78 0.0000
F4     26 60.47 24 3.82 38.5 18.5 80.4 60.47 96.18 0.0000
F5    30 69.77 43 6.84 31.4 15.3 64.65 69.77 93.16 0.0000
F1 without  1 2.33 81 12.88 0.16 0.02 1.19 2.33 87.12 0.0408
(F3 or/and F5)*
F1 and  39 90.70 51 8.16 110.5 39.4 307.9 90.70 91.84 0.0000
(F3 or/and F5)**
F4 without F1  2 4.65 18 2.86 1.66 0.37 7.38 1.09 97.13 0.5041
and without F2***
* HNPCC closely associated cancer in first degree relative of CRC patient; none of these cancers were diagnosed under the age of 50. 
** HNPCC closely associated cancer in first degree relative of CRC patient; at least one of cancers was diagnosed under the age of 50.
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with CRC. Previous studies by Percesepe et al. were
performed using a different methodology [17]. For the
assessment of independent significance of each feature
they applied multivariate analysis. In order to exclude
potential errors of their analyses we decided to apply
in our approach the more direct verification of early
onset of CRC as an independent HNPCC predictor by
excluding from the analysis the “age at diagnosis“ in
cases that matched other criteria.
The methodologies applied in the current study were
undertaken because results of a molecular search for
MSH2/MLH1 mutations were simultaneously performed
in our center – in none of the 10 sporadic CRCs
diagnosed under the age of 40, were we able to detect
molecular genetic changes. Thus, together with results
of nuclear pedigree studies presented herein, we have
verified the utility of nuclear pedigree criteria for the
identification of HNPCC families.
Park et al. reported the occurrence of MSH2/MLH1
mutations among 6% (3 of 50 cases) of sporadic early
onset CRCs [16]. The proportion of mutations in
HNPCC genes in unselected CRCs is between 2-3%.
The results reported by Park et al. suggest that in
patients with sporadic early onset CRC the probability
of finding DNA mismatch repair gene mutations is
more than twice as high. In relation to our results,
Park’s findings can be explained by a bias brought
about by the small number of cases used in their study. 
The results of our study strongly indicate that caution
must be taken in defining the criteria of diagnosis for
genetic disorders and the usefulness of the methodological
approach developed in this report. Wherever possible,
analyses for independent significance of the studied
features should be verified by the construction of subgroups
that define the potential criteria for selection. 
We believe that the criteria defined in this report
can be further improved. There are several other
pedigree/clinical  features  of  potential  diagnostic
significance such as, right-sided tumor localization,
tumor multiplicity or mucinous histology of CRC [17].
In order to develop more accurate criteria it is
crucial to register a much larger number of HNPCC
cases displaying a series of specific features. In our
experience, nuclear pedigree criteria of suspected
HNPCC defined in this paper are of enormous practical
significance for the identification of HNPCC families
subsequent to DNA testing and surveillance.
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